Navigation Links
Accuray Reschedules Announcement of Results for First Quarter of Fiscal 2009
Date:10/29/2008

s cash and investment balances at the end of the quarter totaled $162.1 million, which includes cash and cash equivalents of $27.2 million, short-term investments of $91.5 million and long-term investments of $38.0 million. At the end of the first quarter the company continued to have zero debt.

"We regret the delay in release of full financial results," said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray. "This is not in any way attributable to the current economic environment. In fact our sales pipeline remains strong. We look forward to discussing our full financial results on November 6th."

Outlook

The following statement is forward-looking and actual results may differ materially. Accuray maintains revenue guidance for fiscal 2009 of $230 million to $250 million.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non- invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the
'/>"/>

SOURCE Accuray Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Accuray Incorporateds CEO to Speak at UBS Global Life Sciences Conference
2. Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO
3. Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008
4. Accuray Incorporateds CEO to Speak at CitiGroup Healthcare Conference
5. Accuray Wins Innovations in Healthcare(SM) ABBY Award
6. Accuray to Present at Citi Investment Research Small & Mid-Cap Conference
7. Accuray Announces New Treatment Planning Service Offering
8. Accuray Incorporateds CEO to Speak at Piper Jaffray 19th Annual Health Care Conference
9. Schering-Plough Reschedules Time of Conference Call, Webcast for 2008 Second Quarter Earnings to Later Today
10. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
11. Electrochromic Display Technology Announcement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval ... for the use of Medtronic,s SynchroMed ® II ... for use with United Therapeutics, Remodulin ® (treprostinil) ...
(Date:12/24/2014)... Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ...
(Date:12/24/2014)... December 23, 2014 “Preparative & ... HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, ... & Agriculture) - Forecasts to 2019” provides a ... opportunities, current market trends, and strategies impacting the ...
(Date:12/24/2014)... December 23, 2014 Earlier this year in ... director of the Adult Stem Cell Technology Center, LLC ( ... appreciated unique property of adult tissue stem cells. His ... Past, Important for the Future,” embodied the essence of his ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... Total acquisition price will be $215 million , ... for infectious disease , , CARLSBAD, ... (Nasdaq: ISIS ) and Abbott (NYSE: ABT ... the remaining equity ownership in Ibis Biosciences, Inc., an Isis subsidiary, ...
... ... (PRWEB) December 17, 2008 -- Facilitating the entry of ... analyzer, now updated to effortlessly examine not only the wireless interface ... but also the interface between the device CPU and the Bluetooth ...
... receives the AARC Zenith Award for Equipment and Service ... Anaheim , , IRVINE, ... ), the inventor of Pulse CO-Oximetry and Measure-Through-Motion and ... its remote monitoring and clinician notification system, Masimo Patient ...
Cached Biology Technology:Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis 2Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis 3Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis 4Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis 5Newly Available To Medical Device Manufacturers - Bluetooth Testing Equipment 2Newly Available To Medical Device Manufacturers - Bluetooth Testing Equipment 3AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in 'Improving Patient Outcomes and Reducing Costs' in Post-Acute Care Facilities 2AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in 'Improving Patient Outcomes and Reducing Costs' in Post-Acute Care Facilities 3AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in 'Improving Patient Outcomes and Reducing Costs' in Post-Acute Care Facilities 4AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in 'Improving Patient Outcomes and Reducing Costs' in Post-Acute Care Facilities 5
(Date:12/22/2014)...  NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" ... growing mobile commerce market, announces it has retained famous pickpocket, ... 2015 International CES debut of the Wocket™ biometric smart wallet.  ... the NXT-ID booth January 6th and 7 th , 2015, ...
(Date:12/19/2014)... MOUNTAIN VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., ... a study that pinpoints fine-scale differences in genetic ancestry of ... Since immigrants first arrived more than four hundred ... served as a meeting place for peoples from different continents. ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... New results presented at 3rd European Lung Cancer Conference ... improve the diagnosis and treatment of malignant pleural mesothelioma, ... lungs caused by asbestos exposure. Micro RNAs ... small molecule that is more abundant in the blood ...
... Lugano-CH/Aurora-US-CO/Geneva-CH, 18 April 2012 -- A new genetic signature ... and objective information about which patients with early stage ... relapse following surgery, investigators report at the 3rd European ... new avenues for immunotherapy for lung cancer. Non-small ...
... to increase loblolly pine production in the Southeast has improved ... climate change, according to a new study by North Carolina ... that grow faster and produce more wood, and what this ... environmental quality by scrubbing as much carbon out of the ...
Cached Biology News:Promising developments in early diagnosis and treatment of mesothelioma 2Promising developments in early diagnosis and treatment of mesothelioma 3Promising developments in early diagnosis and treatment of mesothelioma 4Gene signature helps identify risk of relapse in lung cancer patients 2
Peptide-affinity Purified Polyclonal Antibody to Sphingolipid Receptor Edg8/S1P5...
Peptide-affinity Purified Polyclonal Antibody to MAML1 / Mastermind Peptide with sequence VLPTCPMAEFALPR, from N Terminus of the protein sequence according to NP_055572....
DNA sequencing - plasmids or PCR fragments, 3-7 working days service....
LEAF™ Purified anti-human/mouse/rat ICOS...
Biology Products: